- 产品参数
- 产品详情
- 说明书
- 相关产品
发货周期：
干冰冻存管运输3天（1x106cells/冻存管x2）
常温运温1-2周发货 (1x106 cells/T25培养瓶）
原价：1400元 套装价特惠价：890元
4T1是从410.4瘤株中未经诱变筛得的6-硫鸟嘌噙抗性细胞株。当注射到BALB/c小鼠中时，4T1自发产生高转移肿瘤，可转移到肺，肝，淋巴结和大脑，同时在注射部位形成始发灶。诱导转移时不需要摘除始发灶。4T1细胞在BALB/c小鼠中的生长与转移特性与人体中的乳腺癌十分相近。这种肿瘤是人VI期乳腺癌的动物模型。4T1-诱导的肿瘤在手术后及未手术情况下转移的动力学相近，可以用作手术后及未手术模型。跟其他肿瘤模型相比，由于4T1的抗6-硫鸟嘌噙特性，微小的转移细胞团(少到仅仅1个)也可以在许多远端器官中检测到。
细胞名称：小鼠乳腺癌细胞
细胞简称：4T1
产品货号：TCM-C705
种属来源：小鼠
组织来源：乳腺
疾病特征：乳腺癌
细胞形态：上皮细胞样
生长特性：贴壁生长
培养体系：RPMI-1640+10%FBS+1%P/S
配套培养基货号：TCM-G705
传代比例：1:3-1:6，每2-3天换液一次
倍增时间：48-72 h
培养条件：气相：95%空气+5%CO2，温度：37℃
冻存条件：60%基础培养基+30%FBS+10%DMSO，液氮储存
质量检测：细菌、真菌、支原体检测均为阴性
参考文献：
Pulaski BA, et al. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol. Immunother. 49: 34-45, 2000. PubMed: 10782864.
Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493, 1998. PubMed: 9537252.
Pulaski BA, et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res. 60: 2710-2715, 2000. PubMed: 10825145.
Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405, 1992. PubMed: 1540948.
4T1 已发表过的文章：
IF=12.4 Zhang Z, Tang S, Qi M, et al. Mitochondria-targeting natural product rhein conjugated with dichloroacetate as the dual inhibitor of glycolysis and oxidative phosphorylation to off energize cancer cells and induce ROS storm[J]. Theranostics, 2025, 15(11): 4909.
IF=18 Wang Z, Sha T, Li J, et al. Turning foes to friends: Advanced “in situ nanovaccine” with dual immunoregulation for enhanced immunotherapy of metastatic triple-negative breast cancer[J]. Bioactive Materials, 2024, 39: 612-629.
IF=8.2 Li Z, Zhang Z, Qian X. FGF2-targeted Timosaponin AIII provokes ER stress and dampens PI3KAKT signaling pathway in breast cancer. Free Radic Biol Med. 2026 Jan 23:S0891-5849(26)00063-8.
IF=14.3 Fu J, Wu S, Bao N, et al. A Universal Strategy of Anti‐Tumor mRNA Vaccine by Harnessing “Off‐the‐Shelf” Immunity[J]. Advanced Science, 2025, 12(8): 2401287.
IF=10 Sun Y, Peng X, Guan Y, et al. K2FeO4‐Enhanced Photodynamic Therapy of Breast Cancer via In Situ Synthesis of Fe2O3 and O2[J]. Advanced Healthcare Materials, 2025, 14(2): 2402827.
IF=7.9 Hongpeng Duan, Zhiyuan Chen, Xinyue Wang, Bei Zhang, Liangbo Guo, Wenhao Lv, Zhenbin Xu, Shaosheng Wu, Fan Yu, Difan Wang, Weijing Zhang, Yifan Lian, Shengmin Zhang,Biomimetic nanoplatform potentiates STING-immunotherapy by coordinated delivery of chemotherapeutic and innate immune agonist,Materials & Design,Volume 261,2026,115372.
IF=5.8 Zhao H Y, Li K H, Wang D D, et al. A mitochondria-targeting dihydroartemisinin derivative as a reactive oxygen species-based immunogenic cell death inducer[J]. Iscience, 2024, 27(1).
参考链接：4T1 - CRL-2539 |ATCC
20240124180136_312_3586.pdf (cellbank.org.cn)
4T1细胞培养注意事项
(1) 该细胞生长速度快，细胞汇合度越高越难消化，建议分次消化。一次消化至有细胞移动漂浮时终止，再进行二次消化剩余的细胞，尽量消化成单颗细胞，细胞传代第二天有少量细胞团贴壁未展开为正常现象，继续培养细胞会展开；
(2) 若在培养时出现细胞变圆现象，有可能是细胞密度过大，无法展开的原因，可通过降低传代密度来改善。
收货当天如何处理细胞？
收到细胞后请务必仔细阅读产品资料，了解细胞相关信息，如贴壁特性 (贴壁/悬浮/半贴壁半悬浮)、细胞形态、培养体系、传代比例和换液频率等。